Podcasts about biosynthetic

Synthesis, a process that may sound complex, is actually quite common in our daily lives. From the production of everyday items like Advil, organic milk, citric acid, to the creation of vitamins A and D, and multivitamins, synthesis is a key player.Why does this realization often provoke a negative reaction? Perhaps it's because there's a desire for clean, safe, and consistent natural products, especially when they originate from plants.Surprisingly, synthesis enhances our ability to deliver such products.This week, we're joined by Shane Johnson to delve into the following topics: How minors are manufactured, synthetic vs. biosyntheticUpcoming Minors to keep an eye onNovel APIs & AnalogsAbout Dr. Shane JohnsonDr. Shane Johnson's career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.  Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane's work has been focused on the cannabis and cannabinoid science space, and he has developed a strong working knowledge of clinical opportunities in the sector.  He is currently on the Board of Directors of several cannabis-related companies, and is a co-founder of one of Nevada's leading cultivators and producers of premium cannabis products including a patented lozenge. Shane holds a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, an M.D. from the Stanford University School of Medicine, and is a Fulbright Scholar.Guest Links https://www.baymedica.com/https://www.linkedin.com/in/shanejohnson3/https://www.youtube.com/channel/UC-XRZ0FMzcWgFL_mqdAOPRwhttps://twitter.com/BayMedicaFollow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcastThe Dime is a top 50 Cannabis PodcastSign up for our playbook here:

Synthesis, a process that may sound complex, is actually quite common in our daily lives. From the production of everyday items like Advil, organic milk, citric acid, to the creation of vitamins A and D, and multivitamins, synthesis is a key player.Why does this realization often provoke a negative reaction? Perhaps it's because there's a desire for clean, safe, and consistent natural products, especially when they originate from plants.Surprisingly, synthesis enhances our ability to deliver such products.This week, we're joined by Shane Johnson to delve into the following topics: How minors are manufactured, synthetic vs. biosynthetic  Upcoming Minors to keep an eye on  Novel APIs & AnalogsAbout Dr. Shane JohnsonDr. Shane Johnson's career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.  Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane's work has been focused on the cannabis and cannabinoid science space, and he has developed a strong working knowledge of clinical opportunities in the sector.  He is currently on the Board of Directors of several cannabis-related companies, and is a co-founder of one of Nevada's leading cultivators and producers of premium cannabis products including a patented lozenge. Shane holds a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, an M.D. from the Stanford University School of Medicine, and is a Fulbright Scholar.Guest Links https://www.baymedica.com/https://www.linkedin.com/in/shanejohnson3/https://www.youtube.com/channel/UC-XRZ0FMzcWgFL_mqdAOPRwhttps://twitter.com/BayMedicaFollow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcastThe Dime is a top 50 Cannabis PodcastSign up for our playbook here:

Synthesis, a process that may sound complex, is actually quite common in our daily lives. From the production of everyday items like Advil, organic milk, citric acid, to the creation of vitamins A and D, and multivitamins, synthesis is a key player.Why does this realization often provoke a negative reaction? Perhaps it's because there's a desire for clean, safe, and consistent natural products, especially when they originate from plants.Surprisingly, synthesis enhances our ability to deliver such products.This week, we're joined by Shane Johnson to delve into the following topics: How minors are manufactured, synthetic vs. biosynthetic  Upcoming Minors to keep an eye on  Novel APIs & AnalogsAbout Dr. Shane JohnsonDr. Shane Johnson's career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.  Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane's work has been focused on the cannabis and cannabinoid science space, and he has developed a strong working knowledge of clinical opportunities in the sector.  He is currently on the Board of Directors of several cannabis-related companies, and is a co-founder of one of Nevada's leading cultivators and producers of premium cannabis products including a patented lozenge. Shane holds a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, an M.D. from the Stanford University School of Medicine, and is a Fulbright Scholar.Guest Links https://www.baymedica.com/https://www.linkedin.com/in/shanejohnson3/https://www.youtube.com/channel/UC-XRZ0FMzcWgFL_mqdAOPRwhttps://twitter.com/BayMedicaFollow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcastThe Dime is a top 50 Cannabis PodcastSign up for our playbook here:

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.09.515837v1?rss=1 Authors: Wang, L., Park, L., Wu, W., King, D., Medina, A. V., Raven, F., Martinez, J. D., Ensing, A., Yang, Z., Jiang, S., Aton, S. Abstract: Post-learning sleep plays an important role in hippocampal memory processing, including contextual fear memory (CFM) consolidation. Here, we used targeted recombination in activated populations (TRAP) to label context-encoding engram neurons in the hippocampal dentate gyrus (DG) and assessed reactivation of these neurons during post-learning sleep. We find that post-learning sleep deprivation (SD), which impairs CFM consolidation, selectively disrupts reactivation in inferior blade DG engram neurons. This change was linked to more general suppression of neuronal activity markers in the inferior, but not superior, DG blade by SD. To further characterize how learning and subsequent sleep or SD affect these (and other) hippocampal subregions, we used subregion-specific spatial profiling of transcripts and proteins. We found that transcriptomic responses to sleep loss differed greatly between hippocampal regions CA1, CA3, and DG inferior blade, superior blade, and hilus. Critically, learning-driven transcriptomic changes, measured 6 h following contextual fear learning, were limited to the two DG blades, differed dramatically between the blades, and were absent from all other regions. Similarly, protein abundance in these hippocampal subregions were differentially impacted by sleep vs. SD and by prior learning, with the majority of alterations to protein expression restricted to DG. Together, these data suggest that the DG plays an essential role in the consolidation of hippocampal memories, and that the effects of sleep and sleep loss on the hippocampus are highly subregion-specific, even within the DG itself. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Some of the HUGE topics covered in this episode with Karen Kingston: Cov'd-19 injections contain NEUROWEAPONS embedded in Lipid Nanoparticles (LNP) Neurological weapons were hidden through Emergency Use Authorization cover-up Shocking patents confirm it's all true (patent numbers shown) Transhumanism assault on humanity now under way, people becoming LESS human LNPs can be activated via 5G frequencies to achieve physiological changes Cov'd "v-accines" appear to be exotic tech INSTALLED in human hosts CCP-linked AI company named "national security threat" in USA 5G infrastructure to be exploited by AI embedded systems for surveillance Post-Vax "biostructures" are self-assembling biosynthetic weapons Rumble - https://rumble.com/v1n9zh4-biotech-analyst-karen-kingston-unveils-the-covid-vaccine-5g-link-biosynthet.htmlPodcast - https://jsk.transistor.fmPatreon (Donate) - https://patreon.com/ownershipeconomy ★ Support this podcast on Patreon ★

Some of the HUGE topics covered in this episode with Karen Kingston: Cov'd-19 injections contain NEUROWEAPONS embedded in Lipid Nanoparticles (LNP) Neurological weapons were hidden through Emergency Use Authorization cover-up Shocking patents confirm it's all true (patent numbers shown) Transhumanism assault on humanity now under way, people becoming LESS human LNPs can be activated via 5G frequencies to achieve physiological changes Cov'd "v-accines" appear to be exotic tech INSTALLED in human hosts CCP-linked AI company named "national security threat" in USA 5G infrastructure to be exploited by AI embedded systems for surveillance Post-Vax "biostructures" are self-assembling biosynthetic weapons Rumble - https://rumble.com/v1n9zh4-biotech-analyst-karen-kingston-unveils-the-covid-vaccine-5g-link-biosynthet.htmlPodcast - https://jsk.transistor.fmPatreon (Donate) - https://patreon.com/ownershipeconomy ★ Support this podcast on Patreon ★

- Covid-19 injections contain NEUROWEAPONS embedded in Lipid Nanoparticels (LNP) - Neurological weapons were hidden through Emergency Use Authorization cover-up - Shocking patents confirm it's all true (patent numbers shown) - Transhumanism assault on humanity now under way, people becoming LESS human - LNPs can be activated via 5G frequencies to achieve physiological changes - Covid "vaccines" appear to be exotic tech INSTALLED in human hosts - CCP-linked AI company named "national security threat" in USA - 5G infrastructure to be exploited by AI embedded systems for surveillance - Post-vaccine "biostructures" are self-assembling biosynthetic weapons   For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

References Dr Guerra's lipid and membranes lectures Biochimica et BiophysicaActa (BBA) - Molecular and Cell Biology of Lipids.2014.Volume 1841, Issue 9, Pages 1241-1246 Onco Targets Ther. 2017;10:5491-5524 --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message

In episode 274, Kestrel welcomes Michelle Zhu, the CEO & cofounder of Huue, to the show. In an effort to replace toxic chemical dyes in apparel, Huue are developing biosynthetic dyes — their initial focus is to provide an alternative to synthetic indigo. “We are creating a biosynthetic solution that is a one-to-one drop-in replacement into the textile supply chain. We're creating these bio-identicals that can minimize the footprint of production of these dyes and pigments, but without disrupting the supply chain process that is required to make the authentic look and feel of denim that everybody knows and loves.” -Michelle Zhu Are you familiar with biosynthetics? If so, do you understand what they are or how they operate? So often terms like this get thrown around in the *sustainability* space, without a lot of context or definitions. They are assumed to fall into the good box or the bad box, when yet again – there is a lot more information needed to understand the bigger picture. So, here's the super basics – biosynthetics are made of renewable materials, instead of being petroleum based. We often hear about them from a fiber stance, so fabrics made up of biopolymers from corn or sugar or other ingredients. But on this week's show, we're diving into more on how biosynthetics are being used for textile dyeing.                   Today, the majority of our clothes are colored with synthetic dyes. If we look back, the first synthetic dye was accidentally discovered in the 1850s when an 18-year old chemist was searching for a treatment for malaria. And since then, they've gradually taken over due to their speed and efficacy.  But take indigo – the color that we align with denim. Today, every kilogram of synthetic indigo produced uses 75x the amount of petroleum. And it involves the use of dangerous chemicals like benzene, formaldehyde, and sodamide. This week's guest cofounded a company that's leveraging biosynthetics to address the extreme toxicity across the textile dye industry. They've started with indigo blue, and are building one-to-one solutions that can be inserted directly into the current manufacturing infrastructure.  Quotes & links from the conversation: “This Melinda Gates-backed biotech startup is growing bacteria that make sustainable dye for denim”, article in Fast Company "How These Founders Are Detoxifying the Denim Industry--and Saving the Planet", article in Inc. "Using synthetic biology platforms to clean up indigo dye-making", article in Axios "Best Inventions of 2021 - Huue: Blue Jeans Go Green", article in TIME Huue's Website > Follow Huue on Instagram >

Group V esters are interesting, inasmuch as the term "ester" only really refers to a single functional group. The capacity to tailor the "r" alkyl groups around these are infinite, and there are a number of small-batch companies producing highly customised esters for lubricating oils. Biosynthetic Technologies is known for the Estolides - a form of ester that is very resistant to hydrolysis. The other advantage is the capacity to produce sustainable lubricants at scale; this could very well be the future of the industry. Biosynthetic Technologies YouTube Channel: https://youtube.com/channel/UCC-rip-p6HtahQyeQclHBnw Biosynthetic Technologies Website: https://www.biosynthetic.com/005

Hosts: Carly Blankenship and Merrill Bettis Guest Speaker: Dr. Jennings Dr. Jennings is the esteemed Associate Professor in the Chemistry and Biochemistry department here at UA; today, he spoke about his current research and his personal tie to it, student manipulation of data in major labs, and the effects of COVID-19 on researchers across the nation. Read more about Dr. Jennings and his research on the UA Directory! https://chemistry.ua.edu/people/michael-p-jennings/

PsyBio Therapeutics Corp (TSXV:PSYB) (OTCMKTS:PSYBF) CEO Evan Levine tells Proactive it is starting to manufacture proprietary biosynthetic psychedelic compounds in Europe. Tevine says the initial pilot-scale batch manufacturing run is the Florida-based company's first in the continent, and is working with France's Biose Industrie, which commercializes pharmaceutical products based on live bacterial production,

PsyBio Therapeutics Corp (CVE:PSYB) CEO Evan Levine tells Proactive it has initiated process development of its proprietary biosynthetic formulation of norbaeocystin in collaboration with the Advanced Biofuels and Bioproducts Process Development Unit, a scale-up facility managed by Lawrence Berkeley National Laboratory. Levine says norbaeocystin is an analogue of psilocybin. It has commenced Phase I of the formulation process, including analytical chemistry technical transfer to establish detection methods for fermentation products and key feedstocks and metabolites.

Biosynthetic compounds — including cannabinoids — present the 'last great domestication' says Roy Lipski, CEO of Creo. His company is at the forefront of bringing lab-produced cannabinoids to market, at scale.  Cosmetics and creams will be among the first products to take advantage of this technology and we can look for these products on store shelves in the not-too-distant future. Tune in to hear how:Microorganisms can produce bio-identical compounds, without the waste that comes with plant-produced cannabinoids.A lab can produce a year's crop worth of cannabinoids in 48 hours.We can now produce 'rare' cannabinoids, at scale.Creo is working with consumer packaged goods providers to integrate cannabinoids into products  we use every day — like skincare products — and we can expect to see them on store shelves starting in 2022.

Biosynthetic® Technologies recently announced the global launch of their new product line of novel additives for metalworking fluids (MWF) called Biocea™. These novel sustainable additives use the patented estolide technology. These MWF additives are biobased, biodegradable, non-bioaccumulative, and non-toxic. Biocea additives leverage Biosynthetic Technologies' proprietary estolide technology for high demanding water soluble, synthetic, and conventional oil additive applications. Biocea additives, which are produced from castor oil derivatives in India, enhance the lubricity, polarity, film strength, biostability, hydrolytic stability, and oxidative stability of the base fluid. In this podcast, Mark Miller, CEO of Biosynthetic Technologies, talks about this unique biodegradable MWF additive, plus the company's plan in the engine oil space, as it pursues its ILSAC GF-6 certification from the American Petroleum Institute (API) for its estolide base fluids.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.28.358507v1?rss=1 Authors: Steinke, K., Mohie, O. S., Weber, T., Kovacs, A. T. Abstract: Microbes produce a plethora of secondary metabolites that although not essential for primary metabolism benefit them to survive in the environment, communicate, and influence differentiation. Biosynthetic gene clusters (BGCs) responsible for the production of these secondary metabolites are readily identifiable on the genome sequence of bacteria. Understanding the phylogeny and distribution of BGCs helps us to predict natural product synthesis ability of new isolates. Here, we examined the inter- and intraspecies patterns of absence/presence for all BGCs identified with antiSMASH 5.0 in 310 genomes from the B. subtilis group and assigned them to defined gene cluster families (GCFs). This allowed us to establish patterns in distribution for both known and unknown products. Further, we analyzed variations in the BGC structure of particular families encoding for natural products such as plipastatin, fengycin, iturin, mycosubtilin and bacillomycin. Our detailed analysis revealed multiple GCFs that are species or clade specific and few others that are scattered within or between species, which will guide exploration of the chemodiversity within the B. subtilis group. Uniquely, we discovered that partial deletion of BGCs and frameshift mutations in selected biosynthetic genes are conserved within phylogenetically related isolates, although isolated from around the globe. Our results highlight the importance of detailed analysis of BGCs and the remarkable phylogenetically conserved errodation of secondary metabolite biosynthetic potential in the B. subtilis group. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.27.357780v1?rss=1 Authors: Pinkerton, M., Ruetenik, A., Bazylianska, V., Nyvltova, E., Barrientos, A. Abstract: Human neurodegenerative proteinopathies are disorders associated with abnormal protein depositions in brain neurons. They include polyglutamine (polyQ) conditions such as Huntington's disease (HD) and alpha-synucleinopathies such as Parkinson's disease (PD). Overexpression of NMNAT/Nma1, an enzyme in the NAD+ biosynthetic salvage pathway, acts as a powerful suppressor of proteotoxicities in yeast, fly, and mouse models. Screens in yeast models of HD and PD in our lab allowed us to identify three additional enzymes of the same pathway that achieve similar protection against proteotoxic stress: Npt1, Pnc1, and Qns1. Here, we report that their ability to maintain proteostasis is independent of their catalytic activity. Furthermore, we show that, under proteotoxic stress, the four proteins are recruited as molecular chaperones with holdase and foldase activities. In yeast cells, the NAD+ salvage proteins act by preventing misfolding and, together with the Hsp90 chaperone, promoting the refolding of extended polyQ domains or alpha-synuclein. For Nma1, we demonstrate that its foldase activity maps to the C-terminal domain of the protein. The proteostasis activity of Nma1, Npt1, Pnc1, and Qns1 does not require cellular protein quality control systems such as the proteasome or autophagy. We conclude that the entire salvage NAD+ biosynthetic pathway links NAD+ metabolism and proteostasis and emerges as a target for therapeutics to combat age-associated neurodegenerative proteotoxicities. Our observations also illustrate the existence of an evolutionarily conserved strategy of repurposing or moonlighting housekeeping enzymes under stress conditions. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.25.308866v1?rss=1 Authors: Mahootchi, E., Raasakka, A., Luan, W., Muruganandam, G., Loris, R., Haavik, J., Kursula, P. Abstract: Pyridoxal 5'-phosphate (PLP) is an important cofactor for amino acid decarboxylases with many biological functions, including the synthesis of signalling molecules, such as serotonin, dopamine, histamine, -aminobutyric acid, and taurine. Taurine is an abundant amino acid with multiple physiological functions, including osmoregulation, pH regulation, antioxidative protection, and neuromodulation. In mammalian tissues, taurine is mainly produced by decarboxylation of cysteine sulphinic acid to hypotaurine, catalysed by the PLP-dependent cysteine sulphinic acid decarboxylase (CSAD), followed by non-enzymatic oxidation of the product to taurine. We determined the crystal structure of mouse CSAD and compared it to other PLP-dependent decarboxylases in order to identify determinants of substrate specificity and catalytic activity. Recognition of the substrate involves distinct side chains forming the substrate-binding cavity. In addition, the backbone conformation of a buried active-site loop appears to be a critical determinant for substrate side chain binding in PLP-dependent decarboxylases. Phe94 was predicted to affect substrate specificity, and its mutation to serine altered both the catalytic properties of CSAD and its stability. Using small-angle X-ray scattering, we further showed that similarly to its closest homologue, GADL1, CSAD presents open/close motions in solution. The structure of apo-CSAD indicates that the active site gets more ordered upon internal aldimine formation. Taken together, the results highlight details of substrate recognition in PLP-dependent decarboxylases and provide starting points for structure-based inhibitor design with the aim of affecting the biosynthesis of taurine and other abundant amino acid metabolites. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.21.307157v1?rss=1 Authors: Robey, M. T., Caesar, L. K., Drott, M. T., Keller, N. P., Kelleher, N. L. Abstract: Fungi are prolific producers of natural products, compounds which have had a large societal impact as pharmaceuticals, mycotoxins, and agrochemicals. Despite the availability of over 1000 fungal genomes and several decades of compound discovery efforts from fungi, the biosynthetic gene clusters (BGCs) encoded by these genomes and the associated chemical space have yet to be analyzed systematically. Here we provide detailed annotation and analyses of fungal biosynthetic and chemical space to enable genome mining and discovery of fungal natural products. Using 1037 genomes from species across the fungal kingdom (e.g., Ascomycota, Basidiomycota, and non-Dikarya taxa), 36,399 predicted BGCs were organized into a network of 12,067 gene cluster families (GCFs). Anchoring these GCFs with reference BGCs enabled automated annotation of 2,026 BGCs with predicted metabolite scaffolds. We performed parallel analyses of the chemical repertoire of Fungi, organizing 15,213 fungal compounds into 2,945 molecular families (MFs). The taxonomic landscape of fungal GCFs is largely species-specific, though select families such as the equisetin GCF are present across vast phylogenetic distances with parallel diversifications in the GCF and MF. We compare these fungal datasets with a set of 5,453 bacterial genomes and their BGCs and 9,382 bacterial compounds, revealing dramatic differences between bacterial and fungal biosynthetic logic and chemical space. These genomics and cheminformatics analyses reveal the large extent to which fungal and bacterial sources represent distinct compound reservoirs. With a >10-fold increase in the number of interpreted strains and annotated BGCs, this work better regularizes the biosynthetic potential of fungi for rational compound discovery. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.17.240838v1?rss=1 Authors: Kautsar, S. A., van der Hooft, J. J. J., de Ridder, D., Medema, M. H. Abstract: Genome mining for Biosynthetic Gene Clusters (BGCs) has become an integral part of natural product discovery. The >200,000 microbial genomes now publicly available hold information on abundant novel chemistry. One way to navigate this vast genomic diversity is through comparative analysis of homologous BGCs, which allows identification of cross-species patterns that can be matched to the presence of metabolites or biological activities. However, current tools suffer from a bottleneck caused by the expensive network-based approach used to group these BGCs into Gene Cluster Families (GCFs). Here, we introduce BiG-SLiCE, a tool designed to cluster massive numbers of BGCs. By representing them in Euclidean space, BiG-SLiCE can group BGCs into GCFs in a non-pairwise, near-linear fashion. We used BiG-SLiCE to analyze 1,225,071 BGCs collected from 209,206 publicly available microbial genomes and metagenome-assembled genomes (MAGs) within ten days on a typical 36-cores CPU server. We demonstrate the utility of such analyses by reconstructing a global map of secondary metabolic diversity across taxonomy to identify uncharted biosynthetic potential. BiG-SLiCE also provides a "query mode" that can efficiently place newly sequenced BGCs into previously computed GCFs, plus a powerful output visualization engine that facilitates user-friendly data exploration. BiG-SLiCE opens up new possibilities to accelerate natural product discovery and offers a first step towards constructing a global, searchable interconnected network of BGCs. As more genomes get sequenced from understudied taxa, more information can be mined to highlight their potentially novel chemistry. BiG-SLiCE is available via https://github.com/medema-lab/bigslice. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.28.224584v1?rss=1 Authors: Meleshko, D., Korobeynikov, A. Abstract: COVID-19 pandemic has ignited a broad scientific interest in coronavirus research. The identification of coronaviridae species in natural reservoirs often requires de novo assembly. However, existing transcriptome assemblers often are not able to assemble coronaviruses into a single contig. We developed coronaSPAdes, a new module for SPAdes assembler for coronavirus species recovery. coronaSPAdes uses the knowledge about coronaviridae genome structure to improve assembly. We have shown that coronaSPAdes outperforms existing SPAdes modes and other popular short-read assemblers in the recovery of full-length coronavirus genomes. This should allow to better understand the coronaviridae spread and diversity. Copy rights belong to original authors. Visit the link for more info

Russell Cole describes himself as "FUTURIST - EDUCATOR - BUSINESS LEADER, An entrepreneur who is motivated by providing access to technologies and innovations that we should already be benefiting from. I am humbled by the deep network of passionate, caring, professional and incredibly intelligent people I am fortunate to be surrounded by and learn from, daily."In this episode, we start off discussing how Russell got his start in the cannabis industry and his current role as CEO of Organic Grow Solutions. He details the operations of OGS; "We work with cultivators on advanced imaging. So really taking a look at the bio physiology of the crops through imaging solutions and having the opportunity to see what's really going on at the crop level based on wavelengths of light that we can't see what the human eye but these cameras can. We just take photos using these very advanced imaging lenses. We start to look at the different types of light signatures that the plants give off and sometimes that signature indicates that a plant has low nutrient levels or maybe possibly a disease or pest pressure zone that's starting to break out. And we're able to really start to take that information and build data libraries with more precise information”We also get into a discussion on the cannabis industry in a broader sense, comparing the North American and European markets; "they're fortunately able to take the best practices from Canada from other countries that they've seen to develop their policy and regulations behind the medicinal side. What that's doing is, it's stopping the hype from creating a brand sort of propaganda if you will, and just focusing on the validation of it being a medicine today, and really working the system to include pharmacies, studies, and research"Wrapping it up, Russell pulls it all together and shares his live vision; "My life vision is taking technologies, call it cannabis, call it anything a biosynthetic, 3d printed organs in the future and other technologies that that I think are very valuable to society, but are there are barriers to accessing those technologies and we've seen that with cannabis, whether it's because of government regulations and prohibition or whether it's because of costs, whether it's because of data. I think that bringing access to the things that humans could really value from is a mission I'm on and whether again that's cannabis or biosynthetic 3d printed organs, I think it's very important to commercialize and accelerate and lobby and push the boundaries. Yep. And that's mostly my thought is just giving access to people and accelerating our development towards making sure that our world can, just improve."Thanks, Russell for your dedication, vision, and work to the cannabis industry and the world in general!Russell's links:LinkedIn: https://www.linkedin.com/in/russellcole/Organic Grow Solutions: https://www.organicgrowsolutions.com/Facebook: https://www.facebook.com/OrganicGrow-Solutions-283257502607493/https://growupconference.com/speakers/russell-cole/

Russell Cole describes himself as "FUTURIST - EDUCATOR - BUSINESS LEADER, An entrepreneur who is motivated by providing access to technologies and innovations that we should already be benefiting from. I am humbled by the deep network of passionate, caring, professional and incredibly intelligent people I am fortunate to be surrounded by and learn from, daily." In this episode, we start off discussing how Russell got his start in the cannabis industry and his current role as CEO of Organic Grow Solutions. He details the operations of OGS; "We work with cultivators on advanced imaging. So really taking a look at the bio physiology of the crops through imaging solutions and having the opportunity to see what's really going on at the crop level based on wavelengths of light that we can't see what the human eye but these cameras can. We just take photos using these very advanced imaging lenses. We start to look at the different types of light signatures that the plants give off and sometimes that signature indicates that a plant has low nutrient levels or maybe possibly a disease or pest pressure zone that's starting to break out. And we're able to really start to take that information and build data libraries with more precise information” We also get into a discussion on the cannabis industry in a broader sense, comparing the North American and European markets; "they're fortunately able to take the best practices from Canada from other countries that they've seen to develop their policy and regulations behind the medicinal side. What that's doing is, it's stopping the hype from creating a brand sort of propaganda if you will, and just focusing on the validation of it being a medicine today, and really working the system to include pharmacies, studies, and research" Wrapping it up, Russell pulls it all together and shares his live vision; "My life vision is taking technologies, call it cannabis, call it anything a biosynthetic, 3d printed organs in the future and other technologies that that I think are very valuable to society, but are there are barriers to accessing those technologies and we've seen that with cannabis, whether it's because of government regulations and prohibition or whether it's because of costs, whether it's because of data. I think that bringing access to the things that humans could really value from is a mission I'm on and whether again that's cannabis or biosynthetic 3d printed organs, I think it's very important to commercialize and accelerate and lobby and push the boundaries. Yep. And that's mostly my thought is just giving access to people and accelerating our development towards making sure that our world can, just improve." Thanks, Russell for your dedication, vision, and work to the cannabis industry and the world in general! Russell's links: LinkedIn: https://www.linkedin.com/in/russellcole/ Organic Grow Solutions: https://www.organicgrowsolutions.com/ Facebook: https://www.facebook.com/OrganicGrow-Solutions-283257502607493/ https://growupconference.com/speakers/russell-cole/

This episode contains: Devon’s going to Vegas for his anniversary and Steven is excited about Celebration. Steven’s house has been under quarantine and is finally getting back to normal. Biological Imperative: Scientists print first 3D heart using patient’s biological materials. https://www.sciencedaily.com/releases/2019/04/190415102242.htm Robot Overlords: A biosynthetic dual-core cell computer. Need we say more? https://www.sciencedaily.com/releases/2019/04/190416081416.htm Sci-Fi: Game of Thrones is finally back! We review episode 1 of this season (SPOILERS). Steven then tells us about the history of Celebration and what was announced at this year’s Celebration. We talk a little about the Rise of Skywalker. We also touch on The Mandelorian, Disney Plus, and Devon’s progress in learning to play piano.

In episode 0.4 we continue experimenting and prototyping content with an interview...from the future. We interview the biosynthetic designer Aslan Reed, covering his firm Aesthesia, their pioneering efforts in the field and the future of genetically engineering products.

Geetanjali Bendale, Ph.D. candidate in bioengineering and member of the team at the Regenerative Neurobiology & Neuroelectronics Laboratory (RNN Laboratory)—UT Dallas, provides a thorough overview of the current advances in nerve regeneration and repair. Geetanjali Bendale received a master's in bioengineering from the University of Texas at Arlington. Her intensive research focuses on complex nerve regeneration mechanisms and the methods for restoring functional recovery via the use of bio-mimetic cues. Bendale is currently working toward her Ph.D. at the RNN Laboratory under the guidance of Mario Romero-Ortega, Ph.D. Dr. Romero is an associate professor of bioengineering at UT Dallas and adjunct faculty in the surgery department at the University of Texas Southwestern Medical Center, the UTA Research Institute, and he is a partner researcher at the University of Wollongong, Australia. The RNN Laboratory is interested in understanding the mechanisms involved in axon guidance and target recognition during development, as well as after an injury. The lab's focus is in the application of this knowledge within translational applications. Some of their specific work pertains to spinal cord injuries and neuroprotection, neuroma prevention, peripheral nerve gap repair, and regenerative peripheral neurointerfaces as applied to the overall command and feel of robotic prosthetic limbs.  Bendale discusses her work at the RNN Laboratory, specifically detailing their study in nerve regeneration and the development of a biosynthetic nerve implant, which can be used to find new molecules and growth factors that aid in nerve regeneration. She details the body's intrinsic response to nerve damage and how many nerves in the limbs can regenerate naturally, but if an injury is severe, she states that the nerve may need some assistance such as a graft perhaps. And she describes the various nerve grafts that are currently FDA approved and being used in clinics today. Additionally, she outlines how the tube structures of these nerve repair conduits work and the time it takes for growth to be generated that leads to complete repair of the damaged nerve. As much research has shown, only a small window of time exists in order to repair nerves properly, in fact, as Bendale comments the time frame could be just a few hours, so after a nerve damage injury occurs timing can be critical. She explains how signals are sent between the proximal and distal ends of the nerve and why this communication is key to repair. The bioengineering specialist provides an overview of one of their upcoming studies that will center on new molecules that help with strengthening, sensory axons, and motor function axons. And she details how the signals and axons coordinate to accomplish the goal of repair, and precisely which molecules are best suited for aiding in recovery. Further, Bendale explains how their research found that due to the architecture of their biosynthetic nerve implant, the growth of select axons was continuous, which was a significant achievement in the area of nerve repair.

This Episode Contains: Life is pleasantly mundane for the most part. Except for a crappy thing that happened to Devon at work. Artificial Butt Rope: “Bigger Proteins, Stronger Threads: Synthetic Spider Silk.” Spider silk is very strong but difficult to harvest. Now, for the first time, scientists have created a biosynthetic spider silk that behaves like the real thing. They were able to use large proteins to make protein changes to make the silk. The strength is expected to increase with this new approach. https://www.sciencedaily.com/releases/2018/08/180821094234.htm Brian Matters: “The Spotlight of Attention is More Like a Strobe Light.” Our perception is actually an illusion as our brain changes from a wide focus to narrow focus four times a second. A study was done on humans while a similar study was done on macaque monkeys and both came to the same conclusion. This implies that this type of changing focus has a long history of evolutionary advantage. https://www.sciencedaily.com/releases/2018/08/180822112415.htm Sci-Fi: There’s some new Star Wars: Armada news. They're coming out with a Super Star Destroyer! Star Wars: X-Wing is also still going strong with 2nd Edition. Devon has finished Ball Lighting by Cixin Liu and really enjoyed it. Steven has read a little of The Three Body Problem (also by Cixin Liu). Steven just finished rereading the Harry Potter series, and Devon just started it. We talk about the difference between the books and movies. We then review the new Netflix show Disenchantment.  

This week we take a closer look at corneal blindness. With corneal transplants in short supply, the recent development of synthetic corneas offers hope in the fight against this leading cause of vision-loss worldwide. Smitha Mundasad speaks to Dr May Griffith about her team's work - creating corneas in a lab. Like this podcast? Please help us by supporting the Naked Scientists

This week we take a closer look at corneal blindness. With corneal transplants in short supply, the recent development of synthetic corneas offers hope in the fight against this leading cause of vision-loss worldwide. Smitha Mundasad speaks to Dr May Griffith about her team's work - creating corneas in a lab. Like this podcast? Please help us by supporting the Naked Scientists

Dr. Riley Williams performs a primary biosynthetic mosaicplasty on the right knee of a patient with a loose osteochondral fragment secondary to an osteochondritis dissecans lesion.

Intr Bio Fall lec : Oxidation phosphorylation. Alternative energy source. Biosynthetic pathways

Intr Bio Fall lec : Oxidation phosphorylation. Alternative energy source. Biosynthetic pathways

Tue, 1 Jan 1985 12:00:00 +0100 https://epub.ub.uni-muenchen.de/8832/1/8832.pdf Scriba, Peter Christian; Schlüter, K. J.; Ball, P.; Lühe, C. von der; Müller-Esch, G.

Tue, 1 Jan 1985 12:00:00 +0100 https://epub.ub.uni-muenchen.de/8831/1/8831.pdf Scriba, Peter Christian; Schlüter, K. J.; Ball, P.; Lühe, C. von der; Müller-Esch, G.

Subunit 9 of mitochondrial ATPase (Su9) is synthesized in reticulocyte lysates programmed with Neurospora poly A-RNA, and in a Neurospora cell free system as a precursor with a higher apparent molecular weight than the mature protein (Mr 16,400 vs. 10,500). The RNA which directs the synthesis of Su9 precursor is associated with free polysomes. The precursor occurs as a high molecular weight aggregate in the postribosomal supernatant of reticulocyte lysates. Transfer in vitro of the precursor into isolated mitochondria is demonstrated. This process includes the correct proteolytic cleavage of the precursor to the mature form. After transfer, the protein acquires the following properties of the assembled subunit: it is resistant to added protease, it is soluble in chloroform/methanol, and it can be immunoprecipitated with antibodies to F1-ATPase. The precursor to Su9 is also detected in intact cells after pulse labeling. Processing in vivo takes place posttranslationally. It is inhibited by the uncoupler carbonylcyanide m- chlorophenylhydrazone (CCCP). A hypothetical mechanism is discussed for the intracellular transfer of Su9. It entails synthesis on free polysomes, release of the precursor into the cytosol, recognition by a receptor on the mitochondrial surface, and transfer into the inner mitochondrial membrane, which is accompanied by proteolytic cleavage and which depends on an electrical potential across the inner mitochondrial membrane.

Thu, 1 Jan 1981 12:00:00 +0100 http://epub.ub.uni-muenchen.de/3636/ http://epub.ub.uni-muenchen.de/3636/1/017.pdf Rüffer, Martina; El-Shagi, Hannemarie; Nagakura, Naotaka; Zenk, Meinhart H. Rüffer, Martina; El-Shagi, Hannemarie; Nagakura, Naotaka und Zenk, Meinhart H. (1981): (S)norlaudanosoline synthase. the first enzyme in the benzylisoquinoline biosynthetic pathway. In: FEBS Letters, Vol. 129, Nr. 1: pp. 5-9.